AstraZeneca’s Ultomiris Hits Phase III Mark in Rare Kidney Disease

An update from AstraZeneca ( (GB:AZN) ) is now available.

AstraZeneca’s rare disease unit Alexion has reported positive interim Phase III data for Ultomiris in adults with immunoglobulin A nephropathy, a rare kidney disease that can progress to end-stage kidney failure. The I CAN trial showed a statistically significant and clinically meaningful reduction in proteinuria at week 34, with rapid effects visible as early as week 10 and a safety profile consistent with prior experience.

The company plans to seek accelerated approval in key markets and will advance the trial to its final analysis, which will measure long-term kidney function outcomes at week 106. If confirmed, the results could position terminal C5 complement inhibition with Ultomiris as a disease-modifying treatment option in IgAN, potentially expanding its commercial footprint and offering a new option for a large, high-need patient population across the U.S., Europe and Japan.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £16500.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Spark’s Take on AZN Stock

According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.

The score is driven primarily by strong underlying financial performance and a constructive earnings outlook (growth guidance and pipeline progress). This is tempered by valuation (P/E ~30), recent free-cash-flow variability, and technical signals that appear overextended despite the broader uptrend.

To see Spark’s full report on AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical group focused on prescription medicines in oncology, rare diseases and biopharmaceuticals, including cardiovascular, renal, metabolism, respiratory and immunology. Its Alexion rare disease division, based in Boston, concentrates on complement biology and develops therapies like Ultomiris for severe, underserved conditions worldwide.

Ultomiris is a long-acting C5 complement inhibitor approved across major markets for disorders including paroxysmal nocturnal haemoglobinuria, atypical haemolytic uraemic syndrome, generalised myasthenia gravis and neuromyelitis optica spectrum disorder. It is administered via weight-based intravenous dosing at extended intervals and is being studied for additional indications as part of a broad development programme.

Average Trading Volume: 2,685,494

Technical Sentiment Signal: Buy

Current Market Cap: £229B

See more insights into AZN stock on TipRanks’ Stock Analysis page.